Genotoxic Effects of some Antituberculosis Drugs and Mixtures in Rats

Abstract

In this study[*], it was aimed to observe, genotoxic effects of antituberculosis drugs and combinations on rats. Animals were treated with 31.5 mg/kg isoniazid (INH), 54 mg/kg rifampicin (RIF), 189 mg/kg pyrazinamide (PYR), 100 mg/kg etham­butol(ETA), INH+RIF+PYR (MIX1) and INH+RIF+PYR+ETA (MIX2) mixtures applied via gavage for 90 days. At the end of the study, blood, liver and kidney samples were taken and evaluated by Comet and Micronucleus techniques. Compared to control group, head intensity decreased, tail intensity and tail migration increased on experiment groups in blood samples. Head intensity of PYR and mixture groups decreased, tail intensity of PYR and mixture groups increased and tail migration of PYR, ETA and mixture groups increased in liver samples. Head intensity decreased and tail intensity increased of INH, RIF, ETA and MIX1 group; tail migration increased of MIX1 group in kidney samples. Compared to control group, micronucleus rate of ETA, RIF and MIX 2 groups increased in experiment groups. In conclusion antituberculosis drugs and their mixtures applied for 90 days causes to double strand break of DNA damage at different degrees in blood, kidney and liver cells in rats.

Key words

antituberculosis drug - genotoxicity - rat - comet - micronucleus

^* This study was supported by the Erciyes University Scientific Research Projects Unit, within the scope of the project with the number of “TSA-10–3262 and presented to 8^th Society of Turkish Toxicology Congress as poster presentation.

• References

• 1 Somoskovi A, Parsons LM, Salfinger M. The molecular basis of resistance to Isoniazid, Rifampin and Pyrazinamide in Mycobacterium tuberculosis. Respir Res 2001; 2: 164-168
• 2 Bruton LL, Lazo JS, Parker KL. Basics pharmacologic treatment. Nobel Book Stores, Istanbul 2009; 1204-1205
• 3 Eminzade S, Uraz FV. Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals. Nutr Metab Lond 2008; 5: 18
• 4 Panchabhai TS, Ambarkhane SV, Joshi AS et al. Against Antitubercular Drugs Induced Hepatic Damage: An Experimental Study. Phytother Res 2008; 22: 646-650
• 5 Petri WA. Tuberculosis, Mycobacterium Avium Complex Disease and Leprae Chemotherapy. In: Brunton LL, Lazo JS, Parker KL. (ed.) Goodman&Gilman’s Pharmacological Basis of Therapeutics. NewYork: McGraw-Hill Press; 2006: 1203-1223
• 6 Nishimura Y, Kurata N, Sakurai E et al. Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities. J Pharmacol Sci 2004; 96: 293-300
• 7 Douglas JG, Mcleod MJ. Pharmacokinetic factors in the modern drug treatment of tuberculosis. Clin Pharmacokinet 1999; 37: 127-146
• 8 Bass JB, Farer LS, Hopewell PC et al. Treatment of tuberculosis and tuberculosis infections in adults and children. Am J Respir Crit Care Med 1994; 149: 1359-1374
• 9 Sarawathy SD, Shyamala Devi CS. Modulating Effect of Liv.100, an Ayurverdic formulation on antituberclosis drug-induced alterations in rat liver microsomes. Phytother Res 2001; 12: 501-505
• 10 Tasduq SA, Singh K, Satti NK et al. Terminalia chebula (fruit) prevents liver toxicity caused by sub-chronic administration of rifampicin, isoniazid and pyrazinamide in combination. Hum Exp Toxicol 2006; 25: 1-8
• 11 Tostmann A, Boeree MJ, Aarnoutse RE et al. Antituberculosis drug-induced hepatotoxicity. Concise up-to-date review. J Gastroenterol Hepatol 2008; 23: 192-202
• 12 Iseman MD. Tuberculosis guide for clinicians. Istanbul: Nobel Book Stores; 2002: 25-29
• 13 Baldan HM, De Rosa HJ, Brunetti IL et al. The effect of rifampicin and pyrazinamide on isoniazid pharmacokinetics in rats. Biopharm Drug Dispos 2007; 28: 409-413
• 14 De Rosa HJ, Baldan HM, Brunetti IL et al. The effect of pyrazinamide and rifampicin on isoniazid metabolism in rats. Biopharm Drug Dispos 2007; 28: 291-296
• 15 Shayakhmetova GM, Bondarenko LB, Kovalenko VM. Damage of testicular cell macromolecules and reproductive capacity of male rats following co-administration of ethambutol, rifampicin, isoniazid and pyrazinamide. Interdiscip Toxicol 2012; 5: 9-14
• 16 Masjedi MR, Heldary A, Mohammadi F et al. Chromosomal aberrations and micronucleui in lymphocytes of patients before and after exposure to anti-tuberculosis drugs. Mutagenesis 2000; 15: 489-494
• 17 Thomas BH, Solomonraj G. Drug interactions with isoniazid metabolism in rats. J Pharm Sci 1977; 66: 1322-1326
• 18 Tice RR, Andrews PW, Singh NP. The single cell gel assay: A sensitive technique for evaluating intracelluler differences in DNA damage and repair. Basic Life Sci 1990; 53: 291-301
• 19 Fenech M. The in vitro micronucleus technique. Fund Mol Mec Mut 2000; 455: 81-95
• 20 Anitha B, Sudha S, Gopinath PM et al. Genotoxicity evaluation of pyrazinamide in mice. Mutat Res 1994; 321: 1-5
• 21 Park BK, Kitteringham NR, Maggs JL et al. The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol 2005; 45: 177-202
• 22 Aboul-Ela EI. Cytogenetic effects of rifampicin in somatic and germinal cells of the mouse. J Appl Toxicol 1995; 15: 325-326
• 23 Awodele O, Olayemı SO, Alımba CG et al. Protective effect of vitamin C and or vitamin E on micronuclei induction by rifampicin in mice. TJHR 2010; 12: 20-25
• 24 Attia SM. Chromosomal composition of micronuclei in mouse bone marrow treated with Rifampicin and nicotine, analyzed by multicolor fluorescence in situ hybridization with pancentromeric DNA probe. Toxicol 2007; 235: 112-118